SCHEMBL10227674

SCHEMBL10227674

Cc1ccc(S(=O)(=O)n2ccc3c(NC4CN(C(=O)OC(C)(C)C)C4)ncnc32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 6/20 0.49
▸ PIK3CD O00329 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PIK3CA P42336 1/20 0.40
▸ NAMPT P43490 1/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HTR6 P50406 2/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP3 P08254 1/20 0.39
▸ MMP7 P09237 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ ADORA1 P30542 1/20 0.38
▸ CNR1 P21554 1/20 0.38
▸ CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10228635 0.93 GPR119 (0.55) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL6128795 0.93 GPR119 (0.55) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL6128886 0.92 GPR119 (0.49) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL2728373 0.92 GPR119 (0.49) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL17545832 0.92 GPR119 (0.49) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL17583115 0.91 GPR119 (0.60) GPR119PIK3CDPIK3CACYP3A4CYP2C9
SCHEMBL17527469 0.91 GPR119 (0.49) GPR119PIK3CDMEN1KMT2APIK3CA
SCHEMBL16765406 0.89 GPR119 (0.43) GPR119PIK3CDMEN1KMT2APIK3CA
SCHEMBL16765407 0.89 GPR119 (0.43) GPR119PIK3CDMEN1KMT2APIK3CA
SCHEMBL19725938 0.87 NAMPT (0.43) GPR119MEN1KMT2ANAMPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. 2017-02-02 — — US disclosed
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. 2017-02-02 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
US-9273028-B2 Heterocyclic tyrosine kinase inhibitors BIOGEN MA INC. (US) 2016-03-01 — — US disclosed
WO-2012058645-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2012-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170027956-A1 HETEROCYCLIC TYROSINE KINASE INHIBITORS TEC, ABL1, LCK GPR119 4073/4885PIK3CD 108/4885MEN1 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback